Trial Profile
Uptravi (SelexiPag): tHe usErs dRug rEgistry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms SPHERE
- Sponsors Actelion Pharmaceuticals
- 26 Oct 2021 Status changed from active, no longer recruiting to completed.
- 16 Mar 2021 Planned End Date changed from 30 Jun 2022 to 21 Sep 2021.
- 16 Mar 2021 Planned primary completion date changed from 30 Jun 2022 to 21 Sep 2021.